2,6-Difluoro-4-(methylthio)benzyl alcohol | 1428234-48-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,6-Difluoro-4-(methylthio)benzyl alcohol
• 英文别名: (2,6-difluoro-4-methylsulfanylphenyl)methanol
• CAS: 1428234-48-3
• 化学式: C₈H₈F₂OS
• 分子量: 190.21
• InChiKey: IVXNURDCSQCVAF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  45.5
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Azabenzimidazole derivatives as agonists of the AMP-activated protein kinase
  申请人：Boehringer Ingelheim International GmbH

  公开号：US10307402B2

  公开（公告）日：2019-06-04

  The present invention relates to compounds of general formula I, wherein the group R1, X and Y are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the AMP-activated protein kinase (AMPK) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

  本发明涉及通式 I 的化合物，其中基团 R1、X 和 Y 的定义如权利要求 1 所述，这些化合物具有重要的药理特性，特别是能与 AMP 活化蛋白激酶 (AMPK) 结合并调节其活性。这些化合物适用于治疗和预防可受该受体影响的疾病，如代谢性疾病，特别是 2 型糖尿病。
• NEW AZABENZIMIDAZOLE DERIVATIVES AS AGONISTS OF THE AMP-ACTIVATED PROTEIN KINASE
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP3245210A1

  公开（公告）日：2017-11-22
• New Azabenzimidazole Derivatives as Agonists of the AMP-Activated Protein Kinase
  申请人：Boehringer Ingelheim International GmbH

  公开号：US20180028500A1

  公开（公告）日：2018-02-01

  The present invention relates to compounds of general formula I, wherein the group R 1 , X and Y are defined as in claim 1 , which have valuable pharmacological properties, in particular bind to the AMP-activated protein kinase (AMPK) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.
• [EN] NEW AZABENZIMIDAZOLE DERIVATIVES AS AGONISTS OF THE AMP-ACTIVATED PROTEIN KINASE<br/>[FR] NOUVEAUX DÉRIVÉS D'AZABENZIMIDAZOLE EN TANT QU'AGONISTES DE LA PROTÉINE KINASE ACTIVÉE PAR L'AMP
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2016113300A1

  公开（公告）日：2016-07-21

  The present invention relates to compounds of general formula I, wherein the group R1, X and Y are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the AMP-activated protein kinase (AMPK) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.